Previous 10 | Next 10 |
- Viralym-M, an allogeneic, off-the-shelf, multi-virus specific T-cell therapy demonstrates 93% of patients achieved a clinical response after treatment of viral infections and disease in patients following allogeneic HSCT - Real-world findings demonstrate significantly hi...
The late clinical-stage cell therapy company, AlloVir, Inc. (ALVR) announced pre-clinical results for ALVR109, an Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy.The data presented at the 62nd American Society of Hematology ASH Annual Meeting over the weekend indicated selective antivir...
- Data presented in an oral presentation at the 62 nd American Society of Hematology Annual Meeting - Proof-of-concept clinical trial underway for high-risk patients with COVID-19 AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced...
Gainers: Enlivex Therapeutics (ENLV) +24%, Cellectar Biosciences (CLRB) +18%, Omeros (OMER) +15%, Trxade Group (MEDS) +13%, AlloVir (ALVR) +10%.Losers: ReWalk Robotics (RWLK) -11%, Precision BioSciences (DTIL) -11%, Merrimack Pharmaceutic...
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the Piper Sandler 32 nd Annual Virtual Healthcare Conference on December 1, 2020. The presentations will be available for registered attendees via the Piper Sandler con...
AlloVir (ALVR): Q3 GAAP EPS of -$0.58 misses by $0.28.Cash, cash equivalents, and marketable securities of $378.5MPress Release For further details see: AlloVir EPS misses by $0.28
- Completed initial public offering raising $317.7M in gross proceeds - Viralym -M ( multi-virus - specific T cell therapy ) registrational study in lead indication in virus-associated hemorrhagic cystitis and proof-of-c...
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support its pipeline of allogeneic, off-the-shelf virus-specific T cell therapies during the 62 ...
CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that health outcomes analyses to be presented at IDWeek™ 2020 demonstrate the economic and clinical burden associated with respiratory tract infecti...
The FDA has signed off AlloVir's ( ALVR +6.0% ) Investigational New Drug application (IND) for ALVR109, an allogeneic, off-the-shelf virus-specific T cell therapy candidate against SARS-CoV-2. More news on: AlloVir, Inc., Healthcare stocks news, Stocks on the move, Read m...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...